Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans.
about
TNF-alpha mediates eosinophil cationic protein-induced apoptosis in BEAS-2B cellsPigment epithelium-derived factor binds to hyaluronan. Mapping of a hyaluronan binding siteBiosynthesis of promatrix metalloproteinase-9/chondroitin sulphate proteoglycan heteromer involves a Rottlerin-sensitive pathwayCD44v6 dependence of premetastatic niche preparation by exosomesMatrix metalloproteinases and the regulation of tissue remodellingCD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance.In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model.Heparanase and hepatocellular carcinoma: promoter or inhibitor?Interstitial fluid: the overlooked component of the tumor microenvironment?Functional characterization of Anopheles matrix metalloprotease 1 reveals its agonistic role during sporogonic development of malaria parasites.FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cellsSyndecan-1 and syndecan-4 are independent indicators in breast carcinomaAcquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells.A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.Clinical significance of urine heparanase in bladder cancer progressionDissection of the osteogenic effects of laminin-332 utilizing specific LG domains: LG3 induces osteogenic differentiation, but not mineralization.Is YKL-40 a new therapeutic target in cancer?Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasisYKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?Epac increases melanoma cell migration by a heparan sulfate-related mechanism.Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.Therapeutically targeting protein-glycan interactionsHeparan sulfate proteoglycans: structure, protein interactions and cell signaling.Plasma YKL-40: a potential new cancer biomarker?Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans.Role of CD44 in tumour progression and strategies for targeting.Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.Role of hyaluronan in angiogenesis and its utility to angiogenic tissue engineering.Proteoglycans in the control of tumor growth and metastasis formation.Induction of perlecan expression and neural cell proliferation by FGF-2 in the developing cerebral cortex: an in vivo study.Dynamic Hyaluronan drives liver endothelial cells towards angiogenesis.
P2860
Q21284187-202B753E-4BC1-485D-9B82-4A925F952593Q24655238-BBE96716-62CB-48EA-88DE-DB52D2D50EACQ28478397-9CA5E5D1-38B6-4177-BE2E-D1F972151603Q28568064-15FB16C1-21E0-455D-95F3-B28F00C61756Q29618747-B196C227-DA9C-486A-BC45-DF8538AFE817Q30500172-2EAF8B5B-0A7F-4005-B8A3-743EE9DCAC8BQ33546150-BCC0359C-9AD7-480D-8EEB-A811FB314B00Q33596487-02584035-274E-4FAD-AD62-B32AB1B9A2A3Q34060641-11F8C9B4-6A1F-4931-8E21-EC08C74F4FD2Q34596259-782E1E3D-1BF8-4187-B108-95B9BA6B92F7Q35082690-63B4ABDD-124F-447E-AEF6-BA09E5646E55Q35441324-A507B4A1-BA46-4790-97F3-ECC892366F3CQ35535743-61C2E12C-F6E6-4FBD-B746-AF412A904BB5Q35823840-B3433FBC-15F0-4730-825C-BC0FE4F67187Q35990705-DFDFB8F2-CC49-470D-BC04-CBD4D8A4B130Q36462810-6B3B961D-6C28-44D9-8049-D8E1CAB444B0Q36499016-D24FCF8E-CBB4-4A02-A180-A6EA6D3F1CC8Q36709555-EB23F676-0400-409E-B2C7-831189E4ABABQ37114794-552E33F2-C7DF-4D57-AB64-A165414DA2C5Q37334247-98B74D59-866E-4496-A751-787F93532566Q37406239-551706F8-3DCC-4086-84FA-E4780A54C51EQ37431129-45D5DA2E-7537-410A-A390-CBE09E19F0B1Q37445949-A28EBBB9-40C6-4169-8CB0-6DCC1E61ABECQ37590177-7CE3A700-655C-4D2D-8BD7-8BD28E274A63Q37605869-0E1AA7F2-9020-4EB1-8D13-E0CE2A38BE8CQ38022773-E6C5ACF5-D2EE-44C5-8EC9-AFE2D90D3C12Q38023546-5169F19E-EEAF-4809-9206-1A62254FDA0BQ38736415-9B5F7FAB-F3FD-43DB-9941-5111BE718CBFQ43189555-3A331869-47BD-4EF2-9F2C-555F2A9E834FQ47667044-741F91E8-97BC-433F-BFF9-69C1FC67C246Q48179991-CEEF7B88-27FD-491D-8D42-BFBF17F8E87DQ55262169-5E1CD04F-66C7-4B96-A883-15ED7B375D53
P2860
Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@ast
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@en
type
label
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@ast
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@en
prefLabel
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@ast
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@en
P356
P1433
P1476
Decreasing the metastatic pote ...... heparan sulfate proteoglycans.
@en
P2093
Fjeldstad K
P304
P356
10.2174/1389450054863662
P577
2005-09-01T00:00:00Z